Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, M5G 1X5, Canada.
Galimedix Therapeutics, Inc., 2704 Calvend Lane, Kensington, 20895, MD, USA.
Neuropharmacology. 2024 Feb 15;244:109737. doi: 10.1016/j.neuropharm.2023.109737. Epub 2023 Oct 11.
The great potential for NMDA receptor modulators as druggable targets in neurodegenerative disorders has been met with limited success. Considered one of the rare exceptions, memantine has consistently demonstrated restorative and prophylactic properties in many AD models. In clinical trials memantine slows the decline in cognitive performance associated with AD. Here, we provide an overview of the basic properties including pharmacological targets, toxicology and cellular effects of memantine. Evidence demonstrating reductions in molecular, physiological and behavioural indices of AD-like impairments associated with memantine treatment are also discussed. This represents both an extension and homage to Dr. Chris Parson's considerable contributions to our fundamental understanding of a success story in the AD treatment landscape.
NMDA 受体调节剂作为神经退行性疾病的可用药靶点具有巨大的潜力，但迄今为止仅取得了有限的成功。美金刚是一个罕见的例外，在许多 AD 模型中均表现出了恢复和预防作用。在临床试验中，美金刚可减缓与 AD 相关的认知功能下降。在此，我们概述了美金刚的基本特性，包括药理学靶点、毒理学和细胞作用。此外，我们还讨论了美金刚治疗与 AD 样损伤相关的分子、生理和行为指标降低的证据。这既代表了对克里斯·帕森博士（Chris Parson）在我们对 AD 治疗领域成功案例的基本理解方面的巨大贡献的扩展和致敬。
